Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Chinese Patent Office
Accenture
McKinsey
Dow
Fuji
Queensland Health
Citi
Julphar

Generated: June 19, 2018

DrugPatentWatch Database Preview

KERYDIN Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Kerydin patents expire, and what generic alternatives are available?

Kerydin is a drug marketed by Anacor Pharms Inc and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-nine patent family members in twenty countries.

The generic ingredient in KERYDIN is tavaborole. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tavaborole profile page.
Drug patent expirations by year for KERYDIN
Pharmacology for KERYDIN
Ingredient-typeBoron Compounds
Drug ClassOxaborole Antifungal
Mechanism of ActionProtein Synthesis Inhibitors
Synonyms for KERYDIN
1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole
174671-46-6
2,1-Benzoxaborole, 5-fluoro-1,3-dihydro-1-hydroxy-
3338AH
5-fluoro-1-hydroxy-3H-2,1-benzoxaborole
5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol
5-fluoro-2,1-benzoxaborol-1(3H)-ol
5-Fluoro-3H-benzo[c][1,2)oxaborol-1-ol
5-fluoro-3H-benzo[c][1,2]oxaborol-1-ol
5-FLUOROBENZO[C][1,2]OXABOROL-1(3H)-OL
AK163946
AKOS006303927
AN 2690
AN-2690
AN-2690(Tavaborole)
AN-2690)
AN2690
BDBM50370987
C7H6BFO2
CHEBI:77942
CHEMBL443052
CS-1058
CTK8H2675
D05VGL
D10169
DB09041
DTXSID00169888
EX-A1086
FT-0697827
Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Anacor Pharmaceuticals/Schering-Plough
Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Merck & Co/Anacor
HSDB 8342
HY-10980
K124A4EUQ3
KB-74687
Kerydin (TN)
KS-00000SPV
LFQDNHWZDQTITF-UHFFFAOYSA-N
MB08883
MFCD10699483
MolPort-027-845-281
NCGC00264110-01
SCH-900340
SCHEMBL500016
ST24044751
Tavaborole
Tavaborole (USAN)
Tavaborole [USAN:INN]
Topical antifungal (onychomycosis), Merck & Co
Trichophyton-targeting antifungal (onychomycosis), Anacor Pharmaceuticals/Schering-Plough
Trichophyton-targeting antifungal (onychomycosis), Merck & Co
UNII-K124A4EUQ3
W-5454
X3699
Z1739256284
ZINC169990691

US Patents and Regulatory Information for KERYDIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for KERYDIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,440,642 Boron-containing small molecules ➤ Sign Up
8,889,656 Boron-containing small molecules ➤ Sign Up
9,353,133 Boron-containing small molecules ➤ Sign Up
7,767,657 Boron-containing small molecules ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Healthtrust
Fish and Richardson
Federal Trade Commission
Accenture
Covington
Mallinckrodt
McKinsey
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.